Dog mobility issues and anxiety are becoming increasingly common in aging dogs who are suffering from osteoarthritis and chronic pain. Impaired mobility can also trigger stress-related behaviors such as disrupted sleep, pacing, and restlessness. This clearly emphasizes the connection between physical discomfort and emotional health. Due to the growing demand for effective dog arthritis treatment, veterinarians are combining traditional therapies with supportive options, such as dog calming chews and calming treats, to help calm an anxious dog. Hence, there is a rise in interest in alternative therapies that can support both mobility and anxiety through improved absorption and bioavailability.
Current Medications and Supportive Therapies for Dog Mobility and Anxiety
The current approach for treating dog arthritis is multifaceted, focusing on improving mobility and quality of life. The first line of therapy used is NSAIDs such as carprofen, meloxicam, robenacoxib, and grapiprant due to their proven ability to reduce inflammation and chronic joint pain. Other adjunctive medications for canine pain management are gabapentin, pregabalin, and monoclonal antibody therapies such as bedinvetmab, especially for neuropathic pain or long-term mobility decline. As part of a holistic strategy to support mobility, nutraceuticals such as glucosamine and other joint supplements for dogs are also incorporated into treatment plans alongside rehabilitation, hydrotherapy, and weight management. However, some pet owners may hesitate to use these medications due to concerns about potential side effects, functional decline, or personal preferences regarding drug use. Beyond physical discomfort, chronic conditions such as arthritis can also significantly impact a dog’s emotional well-being.
Stress and anxiety are closely related to chronic pain in dogs. Increased fear and anxiety-related behaviors are often seen in dogs suffering from chronic pain. The severity of pain is associated with a higher frequency of anxiety responses and slower recovery. Further, the dogs may become unable to cope with unfamiliar situations and more sensitive to environmental stressors. Common dog anxiety medications include fluoxetine, clomipramine, trazodone, and dexmedetomidine. These drugs work in different ways to help reduce anxiety-related behaviors and promote calmer responses in stressful situations. The downsides of anxiety medications in dogs are drowsiness, gastrointestinal upset, and changes in behavior such as reduced coordination or restlessness. In some cases, they may also affect heart rate or blood pressure, depending on the drug. This is why many pet owners are looking for a combination of both medical and supportive approaches to calm an anxious dog. Hence, there is a clear need for more effective and better-tolerated alternative therapies for dog arthritis treatment and anxiety.
The Potential of Cannabidiol in Pain and Anxiety
Cannabidiol or CBD has emerged as a potential therapeutic in managing pain and anxiety-related disorders in dogs. Studies have shown that CBD for dogs can reduce osteoarthritis-associated pain, improve mobility, and enhance quality of life in dogs with chronic pain conditions. In addition to its analgesic and anti-inflammatory effects, CBD has shown anxiolytic potential through modulation of the endocannabinoid system and activation of serotonin-related pathways, which may help reduce fear, stress responses, and anxiety-related behaviors.
A recent study has even explored the effect of CBD-containing treats on the noise-induced fear among canines. Although this study found limited anxiolytic effects of CBD at the tested dose in dogs exposed to noise-induced stress, the observed modulation of physiological stress markers suggests potential for broader applications. However, more controlled clinical studies are needed to confirm long-term efficacy, optimal dosing, and safety in veterinary patients. Since the CBD is known for its anti-inflammatory and analgesic properties, these findings encourage further exploration of CBD as a complementary approach for managing anxiety associated with osteoarthritis in dogs.
However, the biggest limitation of CBD currently is poor absorption and low oral bioavailability. This increases the need for using higher doses to achieve therapeutic effects, causing side effects such as drowsiness, gastrointestinal upset, and drug interactions. These challenges have encouraged the development of improved delivery systems to enhance CBD effectiveness and reduce dosing requirements.
Trait Biosciences: Bringing CBD to the Forefront
Trait Biosciences has developed a technology that can convert hemp-derived cannabinoids into fully water-soluble forms, addressing key limitations of traditional CBD formulations such as poor bioavailability, inconsistent absorption, and limited membrane permeability. Unlike traditional CBD formulations, CBD82S dissolves easily without oils, emulsifiers, or added particles. The biggest advantage of CBD82S is its suitability for delivery in multiple formats, including oral, topical, inhalable, and injectable. This could open new possibilities for pain relief and dog anxiety medications in the form of dog calming chews and calming treats.
Trait’s CBD has proven its claim with promising results from in vitro testing of CBD82S, which demonstrated improved delivery, biological activity, and systemic performance compared to conventional CBD formulations. The compound shows enhanced membrane permeation across intestinal, skin, and mucosal models, along with increased expression of anti-inflammatory markers in rat skin following topical application. Additionally, its high stability in biological fluids may support prolonged systemic exposure and more sustained therapeutic effects.
CBD82S has shown positive effects in both mobility support and anxiety reduction. Pet owners reported significant improvements in joint pain and mobility after topical application of CBD82S, suggesting potential benefits for dogs with arthritis or other mobility-related conditions. In addition, preclinical findings showed reduced activity in mice, suggesting potential anxiolytic and relaxation-enhancing effects. Together, these results highlight the potential of CBD82S as a supportive therapeutic option for managing both physical discomfort and stress-related symptoms in dogs.
Final Thoughts
The overlap between reduced mobility and anxiety in dogs increases the demand for a more integrated treatment approach that addresses both physical and emotional well-being. Although the current medications and therapies provide meaningful relief, they have limitations in efficacy, tolerability, and side effects, highlighting gaps in long-term management strategies.
Recent advancements in cannabinoid science, including water-soluble formulations like CBD82S, may help bridge some of these gaps by enhancing absorption, consistency, and overall therapeutic reliability. The preliminary findings show potential benefits for joint comfort, mobility, and calming stress-related behaviors, pointing toward a more holistic approach to canine health.
Although further well-controlled clinical studies are required, the evolving evidence base supports continued exploration of CBD-based innovations as complementary options in dog arthritis treatment. With continued research, such approaches may contribute to more effective, better-tolerated strategies for improving quality of life in dogs suffering from pain, mobility decline, and anxiety.
References
- Pye, C., Bruniges, N., Peffers, M., & Comerford, E. (2022). Advances in the pharmaceutical treatment options for canine osteoarthritis. Journal of Small Animal Practice, 63(10). https://doi.org/10.1111/jsap.13495
- Malkani, R., Paramasivam, S., & Wolfensohn, S. (2024). How does chronic pain impact the lives of dogs: an investigation of factors that are associated with pain using the Animal Welfare Assessment Grid. Frontiers in Veterinary Science, 11. https://doi.org/10.3389/fvets.2024.1374858
- Alessandra Di Salvo, Maria Beatrice Conti, & Giorgia della Rocca. (2023). Pharmacokinetics, efficacy, and safety of cannabidiol in dogs: an update of current knowledge. Frontiers in Veterinary Science, 10. https://doi.org/10.3389/fvets.2023.1204526
- Morris, E. M., Kitts-Morgan, S. E., Spangler, D. M., McLeod, K. R., Costa, J. H. C., & Harmon, D. L. (2020). The Impact of Feeding Cannabidiol (CBD) Containing Treats on Canine Response to a Noise-Induced Fear Response Test. Frontiers in Veterinary Science, 7. https://doi.org/10.3389/fvets.2020.569565